UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)

被引：0
|
作者：
Talpaz, M. [1 ]
Jamieson, C. [2 ]
Gabrail, N. [3 ]
Lebedinsky, C. [4 ]
Gao, G. [4 ]
Patki, A. [4 ]
Lui, F. [4 ]
Tefferi, A. [5 ]
Pardanani, A. [5 ]
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[2] Moores UCSD Canc Ctr, Dept Med, La Jolla, CA USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Sanofi Oncol, Cambridge, MA USA
[5] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1113
引用
收藏
页码：458 / 458
页数：1
相关论文
共 50 条
  • [21] A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
    Mascarenhas, John
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro M.
    Berry, Tymara
    Sherman, Laurie
    Dougherty, Souria
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Rizo, Aleksandra
    Verstovsek, Srdan
    BLOOD, 2020, 136
  • [22] The Effect of Fedratinib, a Selective Inhibitor of Janus Kinase 2 (JAK2), on Weight and Metabolic Parameters in Patients with Intermediate (INT)- or High-risk Myelofibrosis (MF)
    Tremblay, Douglas
    Cavalli, Lara
    Banerjee, Sibabrata Raja
    Rose, Shelonitda
    Mascarenhas, John
    BLOOD, 2020, 136
  • [23] A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis
    Pardanani, Animesh D.
    Gotlib, Jason
    Jamieson, Catriona
    Cortes, Jorge
    Talpaz, Moshe
    Stone, Richard M.
    Silverman, Michael H.
    Shorr, Jolene
    Gilliland, D. Gary
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 43 - 44
  • [24] Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)
    Harrison, Claire N.
    Schaap, Nicolaas P. M.
    Zweegman, Sonja
    Jourdan, Eric
    Kiladjian, Jean-Jacques
    Cervantes, Francisco
    Niederwieser, Dietger
    Cortes, Jorge E.
    Passamonti, Francesco
    Reiter, Andreas
    Recher, Christian
    Doehner, Konstanze
    Heidel, Florian H.
    Silver, Richard T.
    Winton, Elliott F.
    Gupta, Vikas
    Ojeda, Emilio
    Gisslinger, Heinz
    Vannucchi, Alessandro M.
    Talpaz, Moshe
    Zhang, Jenny
    Shi, Weiliang
    Mesa, Ruben A.
    BLOOD, 2013, 122 (21)
  • [25] BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
    Lavie, David
    Ribrag, Vincent
    Loschi, Michael
    Yannakou, Costas K.
    Alwan, Maan
    Abulafia, Adi Schacham
    Hernandez-Rivas, Jesus Maria
    Volchek, Yulia
    Fong, Chun Yew
    Bonifacio, Massimiliano
    Kiladjian, Jean-Jacques
    Ianotto, Jean-Christophe
    Garcia Gutierrez, Valentin
    Tucci, Alessandra
    Xicoy, Blanca
    Al-Ali, Haifa Kathrin
    Talpaz, Moshe
    Gerber, Jonathan M.
    Raman, Indu
    Tomuleasa, Ciprian
    Lee-Hoeflich, Si Tuen
    Das, Sharmila
    Wu, Bin
    Zhao, Qian
    Kim, Eunhee
    Esposito, Oriana
    Liu, Yu
    Nikolova, Zariana
    Tehlirian, Christopher
    Coker, Shodeinde
    Ayala, Rosa
    BLOOD, 2023, 142
  • [26] RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL
    Mead, A.
    Clark, R.
    Chacko, J.
    Knapper, S.
    Yin, J.
    Milojkovic, D.
    Farquharson, M.
    Ali, S.
    Garg, M.
    Andrews, C.
    Dawson, M. Ktiouet
    Harrison, C.
    HAEMATOLOGICA, 2014, 99 : 131 - 132
  • [27] Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial
    Harrison, Claire N.
    Clark, Richard E.
    Chacko, Joseph
    Knapper, Steven
    Yin, John
    Milojkovic, Dragana
    Farquharson, Mira
    Ali, Sabra
    Garg, Mamta K.
    Andrews, Christopher
    Csci, Cstat
    Graham, Susan M.
    Mead, Adam J.
    BLOOD, 2013, 122 (21)
  • [28] A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
    Mascarenhas, John
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Komrokji, Rami S.
    Koschmieder, Steffen
    Vannucchi, Alessandro
    Berry, Tymara
    Sherman, Laurie
    Dougherty, Souria
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Rizo, Aleksandra
    Verstovsek, Srdan
    BLOOD, 2021, 138
  • [29] A Randomized, Placebo-Controlled Study of the Pharmacokinetics, Pharmacodynamics, and Tolerability of the Oral JAK2 Inhibitor Fedratinib (SAR302503)in Healthy Volunteers
    Zhang, Meng
    Xu, Christine R.
    Shamiyeh, Elias
    Liu, Feng
    Yin, Jian Y.
    von Moltke, Lisa L.
    Smith, William B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (04): : 415 - 421
  • [30] A randomized, placebo-controlled study of the tolerability, pharmacokinetics, and pharmacodynamics of the oral JAK2 inhibitor SAR302503 in healthy volunteers.
    Zhang, Meng
    Xu, Christine R.
    Shamiyeh, Elias
    Liu, Feng
    Yin, Jianyun
    von Moltke, Lisa L.
    Smith, William B.
    CANCER RESEARCH, 2013, 73 (08)
12345